

Supplementary Material

Duration (days)	Diagnostic (n)	Characterization (n)	Treatment (n)
1	6	4	6
2	5	7	2
3	85	52	48
4	29	17	23
5	15	7	11
6	16	15	4
7	182	100	70
Total	338	202	164

Table S1 Number of AVEM studies (n) relative to their full study duration (days). Note this only includes studies of duration 1-7 days. Note 32 diagnostic, 22 characterization, and 10 treatment studies were not included as the duration was greater than 7 days.

Day	Frequency (n)	Cumulative %
1	188	50.81%
2	67	68.92%
3	40	79.73%
4	32	88.38%
5	22	94.32%
6	12	97.57%
7	7	99.46%
8	1	99.73%
9	1	100.00%

Table S2a Distribution of time (day) since the start of AVEM, until epileptic diagnosis was made in the diagnostic cohort (n=370), with cumulative percentage answered with each additional day. Note that 99% of diagnostic studies were answered by the end of day 7.

Median (hr)	23.248
Q1 (hr)	9.293
Q3 (hr)	59.536
IQR (hr)	50.243
Mean (hr)	39.810
SD (hr)	40.381
Min (hr)	0.0119
Max (hr)	207.148

Table S2b Descriptive statistics for the AVEM duration in the diagnostic cohort (n=370). The median AVEM time needed to answer diagnostic studies was 23.248 hours. 50% of patients required durations between 9.293 (Q1) and 59.536 hours (Q3). The minimum time was 0.0119 hours and the maximum time was 207.148 hours.

Day	Frequency (n)	Cumulative %
1	117	52.23%
2	38	69.20%
3	25	80.36%
4	17	87.95%
5	10	92.41%
6	8	95.98%
7	8	99.55%
8	0	99.55%
9	1	100.00%

Table S3a Distribution of time (day) since the start of AVEM, until epileptic characterization was made in the characterization cohort (n=224), with cumulative percentage answered with each additional day. Note that 99% of characterizing studies were answered by the end of day 7.

Median (hr)	20.535
Q1 (hr)	9.237
Q3 (hr)	57.965
IQR (hr)	48.728
Mean (hr)	39.890
SD (hr)	42.180
Min (hr)	0.281
Max (hr)	208.880

Table S3b Descriptive statistics for the AVEM duration in the characterization cohort (n=224). The median AVEM time needed to answer characterization studies was 20.53 hours. 50% of patients required durations between 9.24 (Q1) and 57.97 hours (Q3). The minimum time was 0.281 hours and the maximum time was 208.880 hours.

Day	Frequency (n)	Cumulative %
1	102	58.62%
2	27	74.14%
3	20	85.63%
4	18	95.98%
5	3	97.70%
6	3	99.43%
7	1	100.00%

Table S4a Distribution of time (day) since the start of AVEM in the treatment cohort (n=174), until sufficient post-treatment assessment is made, with cumulative percentages listed for each additional day. Note that 99% of characterizing studies were answered by the end of day 6.

Median (hr)	18.4369
Q1 (hr)	5.1077
Q3 (hr)	49.1109
IQR	44.0031
Mean (hr)	30.9668
SD (hr)	32.7832
Min (hr)	0.2812
Max (hr)	164.5578

Table S4b Descriptive statistics for the AVEM duration in the treatment cohort (n=174). The median AVEM time needed to answer characterization studies was 18.437 hours. 50% of patients required durations between 5.108 (Q1) and 49.111 hours (Q3). The minimum time was 0.281 hours and the maximum time was 164.558 hours.

Group 1	Group 2	Median difference (hr)	U-statistic	Significance (p)
Diagnostic	Characterization	2.713	-9.215	3.10E-20
Diagnostic	Treatment	4.811	-11.041	2.41E-28
Characterization	Treatment	2.098	1.695	9.00E-02

Table S5a Significant differences were found between diagnostic and characterization groups ($\mu_d = 2.713$, $U = -9.215$, $n_1 = 370$, $n_2 = 224$, Wilcoxin Rank-Sum test, $p < 0.01$), and between diagnostic and treatment groups ($\mu_d = 4.811$, $U = -11.041$, $n_1 = 370$, $n_2 = 174$, $p < 0.01$). Characterization and treatment groups did not differ significantly ($\mu_d = 2.098$, $U = 1.695$, $n_1 = 224$, $n_2 = 174$, $p = 0.09$). μ_d = difference in median, n_1 = sample size 1, n_2 = sample size 2

Group 1	Group 2	Median difference (hr)	U-statistic	Significance (p)
Focal	Generalized	23.266	3.527	4.21E-04

Table 5b Significant differences in AVEM duration were found in the characterization cohort ($n = 224$), between focal (median = 34.22 hrs, $n = 147$) and generalized groups (median = 10.96 hrs, $n = 77$) (Wilcoxin Rank-Sum test).